Effect of a shortened-duration eptifibatide infusion (75 mg) as adjunctive therapy for percutaneous coronary intervention on inhospital cardiovascular outcomes and bleeding

Scott D. Nei, Jeffrey J. Armon, Ross A. Dierkhising, Malcolm R. Bell, Verghese Mathew, Gregory W. Barsness, Narith N. Ou

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

A retrospective cohort analysis was conducted on patients who underwent percutaneous coronary intervention (PCI) before and after a practice change which reduced the infusion duration of eptifibatide from 18 hours to the time required for completion of a single vial of 75 mg initiated during PCI. Primary end points were inhospital cardiovascular events, target vessel revascularization, and major or minor bleeding. The secondary end point was drug cost. A total of 1,647 patients received the standard-duration infusion (18 hours), and 1,237 received the short-duration infusion. The median infusion times were 18.1 hours (interquartile range 17.7 to 18.7) and 6.6 hours (interquartile range 5.6 to 11.3) in the standard- and short-duration groups, respectively. No differences were found for the rate of inhospital cardiovascular events (2.0% vs 1.9%, respectively; p = 0.78) or inhospital revascularization (0.2% vs 0.3%, respectively; p = 0.68). Also, no statistically significant difference was observed in major bleeding (standard 4.3% vs short 4.4%; p = 0.94) or minor bleeding (standard 3.3% vs short 2.3%; p = 0.09). In conclusion, using a shortened infusion reduced eptifibatide use by an average of 1.6 vials at cost savings of $823 per patient and resulted in no difference in inhospital cardiovascular events, revascularization, or bleeding.

Original languageEnglish (US)
Pages (from-to)707-710
Number of pages4
JournalAmerican Journal of Cardiology
Volume115
Issue number6
DOIs
StatePublished - Mar 15 2015

Fingerprint

Percutaneous Coronary Intervention
Hemorrhage
Drug Costs
Cost Savings
Therapeutics
Cohort Studies
eptifibatide

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Effect of a shortened-duration eptifibatide infusion (75 mg) as adjunctive therapy for percutaneous coronary intervention on inhospital cardiovascular outcomes and bleeding. / Nei, Scott D.; Armon, Jeffrey J.; Dierkhising, Ross A.; Bell, Malcolm R.; Mathew, Verghese; Barsness, Gregory W.; Ou, Narith N.

In: American Journal of Cardiology, Vol. 115, No. 6, 15.03.2015, p. 707-710.

Research output: Contribution to journalArticle

Nei, Scott D. ; Armon, Jeffrey J. ; Dierkhising, Ross A. ; Bell, Malcolm R. ; Mathew, Verghese ; Barsness, Gregory W. ; Ou, Narith N. / Effect of a shortened-duration eptifibatide infusion (75 mg) as adjunctive therapy for percutaneous coronary intervention on inhospital cardiovascular outcomes and bleeding. In: American Journal of Cardiology. 2015 ; Vol. 115, No. 6. pp. 707-710.
@article{ef1431441b68448487e9cb52aca0d647,
title = "Effect of a shortened-duration eptifibatide infusion (75 mg) as adjunctive therapy for percutaneous coronary intervention on inhospital cardiovascular outcomes and bleeding",
abstract = "A retrospective cohort analysis was conducted on patients who underwent percutaneous coronary intervention (PCI) before and after a practice change which reduced the infusion duration of eptifibatide from 18 hours to the time required for completion of a single vial of 75 mg initiated during PCI. Primary end points were inhospital cardiovascular events, target vessel revascularization, and major or minor bleeding. The secondary end point was drug cost. A total of 1,647 patients received the standard-duration infusion (18 hours), and 1,237 received the short-duration infusion. The median infusion times were 18.1 hours (interquartile range 17.7 to 18.7) and 6.6 hours (interquartile range 5.6 to 11.3) in the standard- and short-duration groups, respectively. No differences were found for the rate of inhospital cardiovascular events (2.0{\%} vs 1.9{\%}, respectively; p = 0.78) or inhospital revascularization (0.2{\%} vs 0.3{\%}, respectively; p = 0.68). Also, no statistically significant difference was observed in major bleeding (standard 4.3{\%} vs short 4.4{\%}; p = 0.94) or minor bleeding (standard 3.3{\%} vs short 2.3{\%}; p = 0.09). In conclusion, using a shortened infusion reduced eptifibatide use by an average of 1.6 vials at cost savings of $823 per patient and resulted in no difference in inhospital cardiovascular events, revascularization, or bleeding.",
author = "Nei, {Scott D.} and Armon, {Jeffrey J.} and Dierkhising, {Ross A.} and Bell, {Malcolm R.} and Verghese Mathew and Barsness, {Gregory W.} and Ou, {Narith N.}",
year = "2015",
month = "3",
day = "15",
doi = "10.1016/j.amjcard.2014.12.031",
language = "English (US)",
volume = "115",
pages = "707--710",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Effect of a shortened-duration eptifibatide infusion (75 mg) as adjunctive therapy for percutaneous coronary intervention on inhospital cardiovascular outcomes and bleeding

AU - Nei, Scott D.

AU - Armon, Jeffrey J.

AU - Dierkhising, Ross A.

AU - Bell, Malcolm R.

AU - Mathew, Verghese

AU - Barsness, Gregory W.

AU - Ou, Narith N.

PY - 2015/3/15

Y1 - 2015/3/15

N2 - A retrospective cohort analysis was conducted on patients who underwent percutaneous coronary intervention (PCI) before and after a practice change which reduced the infusion duration of eptifibatide from 18 hours to the time required for completion of a single vial of 75 mg initiated during PCI. Primary end points were inhospital cardiovascular events, target vessel revascularization, and major or minor bleeding. The secondary end point was drug cost. A total of 1,647 patients received the standard-duration infusion (18 hours), and 1,237 received the short-duration infusion. The median infusion times were 18.1 hours (interquartile range 17.7 to 18.7) and 6.6 hours (interquartile range 5.6 to 11.3) in the standard- and short-duration groups, respectively. No differences were found for the rate of inhospital cardiovascular events (2.0% vs 1.9%, respectively; p = 0.78) or inhospital revascularization (0.2% vs 0.3%, respectively; p = 0.68). Also, no statistically significant difference was observed in major bleeding (standard 4.3% vs short 4.4%; p = 0.94) or minor bleeding (standard 3.3% vs short 2.3%; p = 0.09). In conclusion, using a shortened infusion reduced eptifibatide use by an average of 1.6 vials at cost savings of $823 per patient and resulted in no difference in inhospital cardiovascular events, revascularization, or bleeding.

AB - A retrospective cohort analysis was conducted on patients who underwent percutaneous coronary intervention (PCI) before and after a practice change which reduced the infusion duration of eptifibatide from 18 hours to the time required for completion of a single vial of 75 mg initiated during PCI. Primary end points were inhospital cardiovascular events, target vessel revascularization, and major or minor bleeding. The secondary end point was drug cost. A total of 1,647 patients received the standard-duration infusion (18 hours), and 1,237 received the short-duration infusion. The median infusion times were 18.1 hours (interquartile range 17.7 to 18.7) and 6.6 hours (interquartile range 5.6 to 11.3) in the standard- and short-duration groups, respectively. No differences were found for the rate of inhospital cardiovascular events (2.0% vs 1.9%, respectively; p = 0.78) or inhospital revascularization (0.2% vs 0.3%, respectively; p = 0.68). Also, no statistically significant difference was observed in major bleeding (standard 4.3% vs short 4.4%; p = 0.94) or minor bleeding (standard 3.3% vs short 2.3%; p = 0.09). In conclusion, using a shortened infusion reduced eptifibatide use by an average of 1.6 vials at cost savings of $823 per patient and resulted in no difference in inhospital cardiovascular events, revascularization, or bleeding.

UR - http://www.scopus.com/inward/record.url?scp=84926189452&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84926189452&partnerID=8YFLogxK

U2 - 10.1016/j.amjcard.2014.12.031

DO - 10.1016/j.amjcard.2014.12.031

M3 - Article

C2 - 25604931

AN - SCOPUS:84926189452

VL - 115

SP - 707

EP - 710

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 6

ER -